The estimated Net Worth of Dave Helsel is at least $2.8 Milhão dollars as of 19 July 2023. Dave Helsel owns over 4,371 units of Haemonetics stock worth over $2,366,217 and over the last 13 years Dave sold HAE stock worth over $432,511.
Dave has made over 10 trades of the Haemonetics stock since 2012, according to the Form 4 filled with the SEC. Most recently Dave exercised 4,371 units of HAE stock worth $316,679 on 19 July 2023.
The largest trade Dave's ever made was selling 5,000 units of Haemonetics stock on 29 July 2022 worth over $112,200. On average, Dave trades about 972 units every 122 days since 2012. As of 19 July 2023 Dave still owns at least 32,660 units of Haemonetics stock.
You can see the complete history of Dave Helsel stock trades at the bottom of the page.
Dave's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, eBrad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: